Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.27%AUDUSD-1.14%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.84%GBPCAD+0.79%EURGBP-0.66%USDCAD+0.66%GBPNZD+0.64%EURAUD+0.62%AUDNZD-0.62%USDTHB+0.58%EURUSD-0.54%CHFJPY-0.53%NZDUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.41%CADJPY-0.38%NZDCHF+0.33%AUDCHF-0.32%GBPHKD+0.32%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%USDJPY+0.27%EURJPY-0.27%NZDJPY-0.24%USDCNH-0.19%CADCHF+0.19%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%NZDCAD+0.14%EURZAR+0.13%USDZAR+0.13%GBPUSD+0.13%EURCAD+0.12%GBPZAR+0.12%CHFNOK+0.08%EURNOK+0.05%USDMXN+0.04%EURCZK-0.04%USDCOP-0.04%USDNOK+0.04%CHFSGD+0.04%USDHKD+0.04%NZDMXN+0.03%AUDNOK+0.03%CHFSEK+0.03%EURPLN+0.02%USDPLN+0.02%NZDSGD+0.02%AUDDKK-0.02%USDSGD+0.01%EURSGD+0.01%EURHKD-0.01%USDDKK-0.01%USDSEK0.00%EURCNH0.00%EURDKK0.00%AUDSGD0.00%EURNZD0.00%GBPSGD0.00%EURSEK0.00%XPTUSD-0.89%XAGUSD-0.57%GAGUSD-0.57%W1+0.35%HG1-0.32%GAUUSD-0.31%XAUUSD-0.31%C1+0.25%XNGUSD+0.24%UKOIL+0.11%S1-0.04%USOIL-0.02%BTCUSD-0.21%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT+0.69%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.47%XLMUSD+1.62%BCHUSDT-0.42%UNIUSD-0.35%LTCUSD+0.07%HBARUSDT+2.15%SUIUSD+0.79%TONUSD+15.77%TAOUSDT+0.18%AAVEUSD-3.68%DOTUSDT+2.53%ICPUSDT-3.21%ONDOUSDT-0.38%WLDUSDT+10.51%ARBUSDT-0.27%JUPUSDT-0.20%ATOMUSDT+1.34%INJUSDT-2.67%STXUSDT+17.38%FETUSDT+2.30%SEIUSDT+0.33%PYTHUSDT-2.19%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.08%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.79%POLUSDT-4.26%AXSUSDT+0.76%FARTCOINUSDT-0.41%EOSUSDT+4.76%DYDXUSDT+3.54%GALAUSDT+4.30%ORDIUSDT+1.24%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.27%AUDUSD-1.14%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.84%GBPCAD+0.79%EURGBP-0.66%USDCAD+0.66%GBPNZD+0.64%EURAUD+0.62%AUDNZD-0.62%USDTHB+0.58%EURUSD-0.54%CHFJPY-0.53%NZDUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.41%CADJPY-0.38%NZDCHF+0.33%AUDCHF-0.32%GBPHKD+0.32%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%USDJPY+0.27%EURJPY-0.27%NZDJPY-0.24%USDCNH-0.19%CADCHF+0.19%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%NZDCAD+0.14%EURZAR+0.13%USDZAR+0.13%GBPUSD+0.13%EURCAD+0.12%GBPZAR+0.12%CHFNOK+0.08%EURNOK+0.05%USDMXN+0.04%EURCZK-0.04%USDCOP-0.04%USDNOK+0.04%CHFSGD+0.04%USDHKD+0.04%NZDMXN+0.03%AUDNOK+0.03%CHFSEK+0.03%EURPLN+0.02%USDPLN+0.02%NZDSGD+0.02%AUDDKK-0.02%USDSGD+0.01%EURSGD+0.01%EURHKD-0.01%USDDKK-0.01%USDSEK0.00%EURCNH0.00%EURDKK0.00%AUDSGD0.00%EURNZD0.00%GBPSGD0.00%EURSEK0.00%XPTUSD-0.89%XAGUSD-0.57%GAGUSD-0.57%W1+0.35%HG1-0.32%GAUUSD-0.31%XAUUSD-0.31%C1+0.25%XNGUSD+0.24%UKOIL+0.11%S1-0.04%USOIL-0.02%BTCUSD-0.21%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT+0.69%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.47%XLMUSD+1.62%BCHUSDT-0.42%UNIUSD-0.35%LTCUSD+0.07%HBARUSDT+2.15%SUIUSD+0.79%TONUSD+15.77%TAOUSDT+0.18%AAVEUSD-3.68%DOTUSDT+2.53%ICPUSDT-3.21%ONDOUSDT-0.38%WLDUSDT+10.51%ARBUSDT-0.27%JUPUSDT-0.20%ATOMUSDT+1.34%INJUSDT-2.67%STXUSDT+17.38%FETUSDT+2.30%SEIUSDT+0.33%PYTHUSDT-2.19%TIAUSDT+0.39%IMXUSDT+0.97%GRTUSDT+0.08%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.79%POLUSDT-4.26%AXSUSDT+0.76%FARTCOINUSDT-0.41%EOSUSDT+4.76%DYDXUSDT+3.54%GALAUSDT+4.30%ORDIUSDT+1.24%NOTUSDT+1.55%RONINUSDT+0.85%
HT

Halozyme Therapeutics, Inc. (HALO)

NASDAQ • Healthcare

$110.4
-$1.15 (-1.0%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$111.54
Day Range$110.36 - $111.82
Avg. Volume (3M)2.4M
Market Cap$13B
P/E Ratio31.4
52 Week Range
$61.23$116.85
Next EarningsIn 32 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$480.9M100%
Gross Profitminus cost of goods$401.8M84%
Operating Incomeminus R&D and overhead$287.6M60%
Net Incomeminus taxes and the rest$229.9M48%

In plain terms: out of every $100 in revenue, Halozyme Therapeutics, Inc. keeps $48 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.6B
Net Income (TTM)
$413.5M
EPS (TTM)
$3.52
ROA (TTM)
16.05%
Current Ratio
2.71

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-111.2%Q1 2026-$0.24
+3.2%Q2 2026$1.6
+27.4%Q3 2026$2.28
Next

Nov 2

in 32 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +27.4%

Halozyme Therapeutics beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, with revenue of $481.0 million topping the $402.3 million estimate, +19.6%, as revenue rose ~48% year over year from about $325.7 million. Adjusted EPS of $2.28 topped the $1.79 estimate, +27.4%, and was up from $1.54 a year ago (+48.1% YoY). Profitability remained high, with gross margin at roughly 84% and operating margin near 60%, alongside gross profit of about $401.8 million and operating income of roughly $287.7 million. Net income increased ~39% YoY to about $229.9 million, up from around $165.2 million a year ago. The company generated operating cash flow of about $240.9 million and repurchased roughly $332.7 million of stock during the quarter. Next-period consensus calls for EPS of $2.24 on revenue of $482.3 million.

View full earnings history

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biotechnology company listed on NASDAQ as HALO that develops and commercializes drug-delivery technologies and partnered therapies. Its business centers on ENHANZE, and the company generated $1.4 billion in FY2025 revenue through products that move injectable medicines into subcutaneous use and through related collaboration economics.

Name
Halozyme Therapeutics, Inc.
CEO
Helen I. Torley
Website
www.halozyme.com
Industry
Healthcare
Year Founded
1998
Employees
423

Today's Snapshot

AI-generated

HALO closed 1% below yesterday's close, in line with a weaker sector. Halozyme appointed Jim Daly, a biopharmaceutical executive, to its board.

Trading Volume

Below 10d avg (3.5M)

2.4M

vs S&P 500 Today

Underperforming Market

-1.23%

Updated: September 30, 2026 at 20:15 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
HALO’s technicals lean constructive, supported by a clear trend signal from a rising ADX and price positioned above medium- and long-term moving averages, even though the very short-term averages sit slightly higher. Momentum readings are positive or neutral and volatility is moderate, while on-balance volume is lagging which tempers the strength of the move. The classic pivot sits above the market but does not negate the prevailing upward trend signaled by the ADX and moving averages. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$82.71 - $111.74
    Buy
  • RSI (14)54.91
    Neutral
  • Stochastic %K (14, 3, 3)53.89
    Neutral
  • MACD Level (12, 26)2.89
    Neutral

Peers & Related Assets

JAZZJazz Pharmaceuticals plc
$231.52-0.4%
CORTCorcept Therapeutics Incorporated
$115.23+0.4%
HSICHenry Schein, Inc.
$83.97-1.2%
CAICaris Life Sciences, Inc.
$30.63-2.9%
CYTKCytokinetics, Incorporated
$65.91+0.4%
ATRAptarGroup, Inc.
$121.16-1.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.